How to appeal a UnitedHealthcare atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for atopic dermatitis (ad / eczema)

Cited policy: OptumRx Dupixent (Dupilumab) for Moderate-Severe AD PA

Age >=6 mo per current label. Diagnosis moderate-severe AD with IGA >=3 OR EASI >=16 OR BSA >=10% OR special-site involvement. Inadequate response/intolerance/contraindication to medium-to-high-potency topical corticosteroid AND topical calcineurin inhibitor (>=4 wk each unless AE). Dermatologist or allergist Rx. Reauth at 6 mo with EASI-50 or IGA improvement >=2 or NRS reduction >=4.

How UnitedHealthcare denies atopic dermatitis (ad / eczema) — and how to counter it

Where UnitedHealthcare pushes back: 1) BSA <10% therefore not severe; 2) Must fail phototherapy first; 3) Pediatric label not recognized.

Counter-arguments that hold up: AAD 2024 (Sidbury JAAD) + AAAAI/ACAAI 2023 (Davis) recognize special-site (face/eyelids/hands/genital), NRS >=4, DLQI >=11, sleep disruption, infection as severity-qualifying regardless of BSA. SOLO-1/2 + AD ADOL + LIBERTY-AD-PEDS + LIBERTY-AD-PRESCHOOL pivotal data supports ages 6 mo+. Phototherapy NOT mandated prerequisite per AAD 2024 — listed as parallel option with access barriers (rural, peds time, hyperpigmentation). Dupixent label down to 6 mo per Jun 2022 FDA expansion.

What UnitedHealthcare typically denies for atopic dermatitis (ad / eczema)

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.